Skip to main content
. 2021 Mar 22;11:609334. doi: 10.3389/fonc.2021.609334

Figure 6.

Figure 6

(A) Low tumor mutation burden acted as a protective factor in bladder cancer micro-environments. (B) Combining tumor mutation burden elevated the predictive accuracy of risk score even more than either of them alone. The hazard of “low TMB + high risk score” group showed more survival risk than the other group (Kaplan-Meier analysis, Low Risk score + High TMB; HR = 0.518). (C–E) The correlation between immune cells and tumor mutation burden. The results showed CD8+ T cells and type M1 macrophages positively correlated with tumor mutation burden, while the M2 macrophages were the opposite. (F–I) CD163, CD209, CSF1, and MMD negatively correlated with tumor mutation burden, clarifying the high level M2 macrophages in patients with low tumor mutation burden. (J–M) Combining tumor mutation burden elevated the predictive accuracy of CD163, CD209, CSF1, and MMD even more than either of them alone.